high mobility group 20AGenealiases: HMGX1 · HMGXB1
Q-omics provides the consensus-scored HMG20A profile across patient tissues and cancer cell-line models. HMG20A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HMG20A is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, HMG20A protein abundance shows 22,691 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, HNSC, and LSCC as cancer lineages where HMG20A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMG20A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMG20A survival associations across molecular data types. HMG20A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMG20A RNA expression–survival associations across cancer types. High HMG20A expression shows unfavorable associations in PAAD, UVM and MESO, but favorable associations in KIRC, BRCA and GBM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HMG20A RNA expression.
This table summarizes HMG20A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HMG20A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMG20A shows lower tumor expression in THCA and LUAD and higher tumor expression in HNSC, STAD, BLCA and CHOL. The HNSC box plot shows higher HMG20A RNA expression in tumor versus normal tissue (log2 FC = +0.607, t-test p < 0.001).
This table shows molecular features associated with HMG20A in patient tissues and cancer cell lines. In patient samples, HMG20A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, HMG20A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and UPPER_AERODIGESTIVE_TRACT.
